Bioretec
2.32
EUR
+0.43 %
1,523 following
BRETEC
First North Finland
Medical Equipment & Services
Health Care
Overview
Financials & Estimates
+0.43%
-6.45%
-3.33%
+8.41%
-16.25%
-6.83%
+1.31%
-
-21.1%
Bioretec is a medical technology company. The company specializes in the development of medical devices. The product portfolio includes, for example, implants for pediatric and adult orthopedics and other material for bone and soft tissue injuries. In addition to the main business, service and associated ancillary services are also offered. Bioretec operates worldwide with the largest presence in the Nordic region.
Read moreMarket cap
56.99M EUR
Turnover
1.88K EUR
P/E (adj.) (25e)
-11.59
EV/EBIT (adj.) (25e)
-13.25
P/B (25e)
10.69
EV/S (25e)
7.87
Dividend yield-% (25e)
-
Coverage

Analyst
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
15/5
2025
Business review Q1'25
14/8
2025
Interim report Q2'25
13/11
2025
Business review Q3'25
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types
Resolutions of Bioretec Ltd's Annual General Meeting and the constitutive meeting of the Board of Directors
Bioretec Ltd: Notification in accordance with chapter 9, section 10 of the Securities Market Act on a change in holdings (W&M GmbH)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Bioretec Ltd's Annual Report 2024 published
New shares in Bioretec Ltd subscribed with option rights have been registered into the Trade Register
Mirva Ekman appointed to Bioretec's Management Team as Quality Director
Bioretec: NOTICE OF ANNUAL GENERAL MEETING OF BIORETEC LTD
CE Mark Approval for RemeOs™ Trauma Screw Product Group, featuring four product lines with over 200 individual products, drives global expansion for Bioretec
Bioretec Ltd's Financial Statements 2024 published
Bioretec Ltd's financial statements bulletin 2024: Foundation for future growth in 2024 - CE mark received in January 2025
Inside information: Bioretec Ltd. receives CE mark approval for RemeOs™ Trauma Screw product portfolio, allowing market launch in Europe
Proposals of the Shareholders' Nomination Board of Bioretec Ltd to the Annual General Meeting 2025
Bioretec Ltd's schedule for financial reporting in 2025
The Finnish Financial Supervisory Authority has imposed a penalty payment on a member of Bioretec's Board of Directors for late notification of managers' transactions
